FDA warned Moor Herbs that its herbal products are unapproved drugs with disease claims and are made without required supplement quality controls.
What happened
FDA inspected the manufacturing facility from February 13, 2023 to March 16, 2023, and reviewed moorherbs.com in May 2023. FDA found website claims that products such as “Full Body Antibiotic,” “Anti-Viral,” and “Tumor Release” treat diseases including infections, HIV, and cancer, making them unapproved new drugs. The inspection also found dietary supplement manufacturing quality rule failures, including missing specifications, no quality control program, and missing or incomplete production records.
What FDA found
FDA says the products are unapproved new drugs because the website claims they cure or treat diseases such as infections, HIV, and cancer without FDA approval.
FD&C Act §§ 201(p), 301(d), 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]FDA says the products are misbranded because they lack adequate directions for use for diseases that a layperson cannot safely self-treat.
FD&C Act § 502(f)(1) [21 U.S.C. 352(f)(1)]FDA says the company did not set required specifications for the identity, purity, strength, and composition of components like Coltsfoot, Wild Cherry Bark, and Boneset Herb.
21 CFR 111.70(b)(1)-(2)FDA says the company did not set labeling specifications or finished-product specifications for identity, purity, strength, composition, and contamination limits.
21 CFR 111.70(d), 111.70(e)FDA says the company had no written quality control procedures or quality control program.
21 CFR 111.103, 111.140(b)(1)FDA says the company lacked master manufacturing records and that batch production records were incomplete.
21 CFR 111.205(a), 111.255(b), 111.260
What FDA wants
FDA asks the company to correct the violations described and to provide adequate evidence and supporting documentation for its corrective actions. The provided letter text does not include a response deadline.
Who should pay attention
- consumers buying herbal disease treatments online
- retailers or distributors selling Moor Herbs products
- dietary supplement brands using similar website claims or lacking CGMP records
This is a summary. Read the original letter on fda.gov.